Atai Life Sciences announces data from Part 2 of Phase 2a study of BPL-003

atai Life Sciences (ATAI) announced positive topline data from Part 2 of Beckley Psytech’s Phase 2a study of BPL-003, for treatment-resistant depression. The findings show that a single dose of BPL-003, when given to patients who were also taking defined selective serotonin reuptake inhibitors, was well-tolerated, with rapid and durable antidepressive effects of up to three months with an average in-clinic treatment time of less than two hours following dosing. The results are also consistent with initial results from Part 1 of the study, which investigated BPL-003 as a monotherapy. Data from that study showed that a single dose of BPL-003 was well-tolerated and produced a rapid and lasting antidepressant effect for up to three months after dosing.